From Medscape Dermatology

25th World Congress of Dermatology (WCD) 2023

July 03 - 08, 2023; Singapore

July 03 - 08, 2023 Singapore

WCD 2023 JAK Inhibitors Effective for AD in Asians, Study Finds Results from a small retrospective clinical study conducted in Singapore found that abrocitinib, baricitinib, and upadacitinib resulted in clearer skin and reduced itch.
Medscape Medical News, July 7, 2023
WCD 2023 Oral IL-23 Blocker for Psoriasis Promising: Phase 2b Study An investigational IL-23R antagonist demonstrated significantly greater efficacy across all doses in patients with moderate to severe psoriasis compared with placebo at week 16 in the FRONTIER 1 study.
Medscape Medical News, July 6, 2023
WCD 2023 Subcutaneous Spesolimab Reduces GPP Flares: Phase 2 Study For generalized pustular psoriasis, treatment with the subcutaneously administered IL-36 receptor antagonist resulted in a significant reduction in flares compared with placebo.
Medscape Medical News, July 5, 2023

Disclaimer

Credit: Anekoho/Dreamstime

Medscape Dermatology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Latest Popular Dermatology News

New JAK Inhibitor Study Data Confirm Benefit in Alopecia Areata The investigational drug deuruxolitinib is effective for hair regrowth in patients with alopecia areata, putting it in line to become second approved JAK inhibitor.
Medscape Medical News, Mar 23, 2023
Phase 3 Prurigo Nodularis Trial Shows Benefit With Nemolizumab From prior studies of nemolizumab, 'we know that it modulates pruritus, but also alters keratinocyte differentiation, inflammation, and fibrosis,' according to Shawn G. Kwatra, MD.
Medscape Medical News, Mar 22, 2023
Expert Shares Her Tips for Diagnosing, Treating Onychomycosis "We need to be antifungal stewards, because resistant dermatophytes are coming," says Dr Boni E. Elewski.
Medscape Medical News, Mar 23, 2023

Related Coverage

Related Resources